

[Click here to view linked References](#)

1
2
3
4 **Association between C-reactive protein levels at hospital admission and long-term**
5
6
7 **mortality in patients with acute decompensated heart failure**
8
9

10
11
12
13
14 Hiroki Matsumoto,^{1,2} Takatoshi Kasai,^{1,2,3} Akihiro Sato,^{1,2} Sayaki Ishiwata,^{1,2} Shoichiro

15
16
17 Yatsu,¹ Jun Shitara,¹ Azusa Murata,¹ Takao Kato,¹ Shoko Suda,¹ Yuya Matsue,^{1,2} Masaru

18
19
20
21 Hiki,¹ Atsutoshi Takagi,^{1,4} Hiroyuki Daida¹
22
23
24
25
26
27

28 ¹Department of Cardiovascular Medicine, Juntendo University School of Medicine,
29
30

31 Tokyo, Japan
32
33
34

35 ²Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of
36
37

38 Medicine, Tokyo, Japan
39
40
41

42 ³Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital, Tokyo,
43
44

45 Japan
46
47
48

49 ⁴Department of Cardiology, Koshigaya Municipal Hospital, Saitama, Japan
50
51
52
53
54
55

56 **Address for correspondence:**
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Takatoshi Kasai, MD, PhD

Department of Cardiovascular Medicine, Juntendo University School of Medicine and
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of
Medicine, Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital.

2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

E-mail: kasai-t@mx6.nisiq.net

Phone: +81-3-3813-3111; Fax: +81-3-5689-0627

1
2
3 **Abstract**
4
5
6

7 **Background:** The C-reactive protein (CRP) levels obtained at hospital admission are
8
9
10 associated with the prognosis of several cardiovascular diseases, including acute
11
12 coronary syndrome. Although the admission CRP level is associated with in-hospital
13
14 mortality in patients with acute decompensated heart failure (ADHF), there are limited
15
16
17 data on the association between the admission CRP level and long-term mortality in
18
19
20
21 patients with ADHF.
22
23
24
25

26
27 **Methods:** This study included consecutive ADHF patients admitted to our institution
28
29
30 from 2007 to 2011. Eligible patients were divided into four groups based on quartiles of
31
32 admission CRP levels. The association between the admission CRP level and long-term
33
34 mortality was assessed by multivariable Cox proportional analysis, including other
35
36 independent variables with p values < 0.1 in the univariable analyses.
37
38
39
40
41
42
43
44

45 **Results:** Overall, 527 eligible patients were examined. There were 142 deaths (27%)
46
47 during a median follow-up period of 2.0 years. In the multivariable analysis, the hazard
48
49 ratio (HR) significantly increased with admission CRP levels in a dose-dependent
50
51
52 manner for mortality (p for trend = 0.034). Multivariable analysis also showed a
53
54
55
56
57
58
59

1
2
3 significant association between the admission CRP level, when treated as a natural
4
5
6
7 logarithm-transformed continuous variable, and increased mortality (HR: 1.16, p =
8
9
10 0.030)
11

12
13
14 **Conclusion:** In patients with ADHF, the admission CRP level was associated with an
15
16
17 increased risk of long-term mortality.
18
19
20
21
22
23

24 **Key words:** heart failure, biomarker, CRP, mortality
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **INTRODUCTION**
4
5
6

7 Heart failure (HF) remains one of the leading causes with increasing cardiovascular
8
9 mortality despite the development of effective treatments [1]. When considering the
10
11 long-term clinical course of HF patients, worsening episodes, which usually manifest as
12
13 acute decompensated HF (ADHF), can be key issues. These episodes can lead to the
14
15 progression of HF itself [2], possibly through alterations in cardiovascular physiology
16
17 and systemic or cardiac biomarkers [3]. Thus, in patients with ADHF, it is important to
18
19 identify factors that show alterations in the acute phase which are associated with an
20
21 increased long-term mortality, and more importantly, which are modifiable [4]. One
22
23 such factor may be systemic inflammation, which has been recognized as an important
24
25 aggravating factor in ADHF [5, 6, 7].^[5-7] The acute-phase reactant against systemic
26
27 inflammation, C-reactive protein (CRP) [8], is widely measured in daily clinical
28
29 practice and routinely in almost all ADHF patients. Many studies suggest that CRP
30
31 levels in patients with chronic HF have a prognostic value [9, 10, 11, 12, 13] [9-13].
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53 However, the prognostic value of CRP levels in patients with ADHF has not been fully
54
55
56
57 elucidated. In particular, limited data are available regarding the association between
58
59

1
2
3 CRP levels at hospital admission for ADHF and the long-term mortality risks. In the
4
5
6
7 present study, we aimed to investigate the prognostic value of admission CRP levels on
8
9
10
11 the long-term mortality of patients with ADHF.

12 13 14 15 16 17 **MATERIALS AND METHODS**

18 19 20 21 **Subjects**

22
23
24 Patients who were admitted to the cardiac intensive care unit in the Juntendo University
25
26
27 Hospital (Tokyo, Japan) with a diagnosis of ADHF between January 2007 and
28
29
30
31 December 2011 were considered for the present study. ADHF was defined based on the
32
33
34
35 modified Framingham criteria [14]. Patients who had acute coronary syndrome and/or
36
37
38
39 had undergone cardiac surgery during the previous 4 weeks or during initial
40
41
42
43 hospitalization, and those with life-threatening malignancies, were excluded. In addition,
44
45
46
47 patients who died during their initial hospitalization, and those without documented
48
49
50
51 admission CRP levels, were excluded.

52
53 The Institutional Review Board of the Juntendo University Hospital approved
54
55
56
57 the study protocol, and the study complied with the Declaration of Helsinki. Informed
58
59
60
61
62
63
64
65

1
2
3 consent was obtained from all patients.
4
5
6
7
8
9

10 **Data collection**

11
12
13 Baseline data were prospectively collected at the time of the initial hospital admission.
14
15

16
17 Medical histories were obtained from the patients' clinical chart reviews. In the present
18
19

20
21 study, a current smoker was defined as one who smoked at the time of admission or had
22
23

24
25 quit smoking less than 1 year prior to admission. The estimated glomerular filtration
26
27

28
29 rate (eGFR) was calculated from baseline serum creatinine levels using the
30
31

32
33 Modification of Diet in Renal Disease equation with a Japanese coefficient [15]. The
34
35

36
37 mean blood pressure (BP) was calculated by using the following formula: mean BP =
38
39

40
41 diastolic BP + $1/3 \times$ (systolic BP - diastolic BP). A complete 2-dimensional
42
43

44
45 echocardiography was performed on each patient. The left ventricular ejection fraction
46
47

48
49 (LVEF) was calculated according to the modified Simpson method. Given that there is
50
51

52
53 no established cutoff value on which to define the admission CRP level in ADHF
54
55

56
57 patients, all eligible patients were classified based on the median CRP value.
58
59

60
61 All patients were followed up from the date of index admission until June
62
63
64
65

1
2
3 2012; outcome data were obtained during a clinical visit or by reviewing the medical
4
5
6
7 records for all recorded deaths. The endpoint of interest was the incidence of all-cause
8
9
10 mortalities. An independent investigator who had no role in the patients' follow-up and
11
12
13 treatment obtained information regarding the outcomes.
14
15
16
17
18
19
20

21 **Statistical analysis**

22
23
24 Continuous variables were expressed as mean \pm standard deviation (SD) or median
25
26
27 (interquartile range). Categorical data were tabulated as frequencies and ratios (%). The
28
29
30 natural logarithm-transformed values were used for the statistical analyses of CRP and
31
32
33 plasma B-type natriuretic peptide (BNP) levels as the original values were skewed. The
34
35
36 baseline characteristics across the three groups were compared using the
37
38
39 Cochran-Armitage test for categorical variables, the analysis of covariance for
40
41
42 continuous variables, and the Kruskal-Wallis test for the New York Heart Association
43
44
45
46 (NYHA) functional class.
47
48
49
50
51

52 Cumulative survival curves were plotted using Kaplan-Meier methods and the
53
54
55 differences in CRP levels across quartiles were determined using log-rank tests. P
56
57
58
59
60
61
62
63
64
65

1
2
3 values of the log-rank trend test were also estimated. Cox proportional hazard models
4
5
6
7 were used to compute the hazard ratios (HR) and 95% confidence intervals (CI) for
8
9
10 each CRP level quartile, using the lowest quartile as the reference group. The HR trend
11
12
13 tests by the CRP quartiles were conducted by assigning an ordinal value to each quartile
14
15
16
17 in separate models. The assumption of proportional hazards was assessed using a
18
19
20
21 log-minus-log survival graph. A univariable Cox proportional hazard analysis was
22
23
24
25 performed by considering the following as independent variables: age, sex, body mass
26
27
28 index (BMI), current smoker, history of ADHF, ischemic heart disease, atrial fibrillation
29
30
31 (AF), diabetes mellitus, chronic pulmonary disease, NYHA functional class, mean BP,
32
33
34
35 heart rate, LVEF, hemoglobin level, eGFR, sodium and potassium serum levels, natural
36
37
38
39 logarithm-transformed BNP levels, and medication use before admission, in addition to
40
41
42 CRP quartiles. Variables with p values < 0.10 in the univariable analysis were included
43
44
45
46 in a multivariable Cox proportional hazard regression analysis. To determine whether
47
48
49 the results differed with the cut-off points, we performed secondary analyses in which
50
51
52
53 CRP levels were treated as a natural logarithm-transformed continuous variable. A
54
55
56
57 p-value of < 0.05 was considered statistically significant. All analyses were performed
58
59
60
61
62
63
64
65

1
2
3 using SPSS version 23 (SPSS Inc., Chicago, IL, USA).
4
5
6
7
8
9

10 **RESULTS**

11 **Baseline characteristics**

12
13
14
15
16
17 Overall, 751 ADHF patients were admitted to our institution between 2007 and 2011.

18
19
20
21 Among them, 160 patients with concomitant acute coronary syndrome and/or those who

22
23
24 had undergone cardiac surgery during the previous 4 weeks, or during initial

25
26
27 hospitalization, as well as those who had life-threatening malignancies, were initially

28
29
30 excluded. A further 52 patients who died during the initial hospitalization and 12

31
32
33 patients without a serum CRP value on admission were also excluded. Finally, 527

34
35
36 patients were targeted and divided into four groups based on their CRP level quartiles:

37
38
39 Quartile 1 [Q1], < 0.3 mg/dL; Quartile 2 [Q2], ≥ 0.3 mg/dL and < 1.0 mg/dL; Quartile 3

40
41
42 [Q3], ≥ 1.0 mg/dL and < 3.9 mg/dL; and Quartile 4 [Q4], ≥ 3.9 mg/dL.
43
44
45
46
47
48

49
50 The baseline characteristics are shown in **Table 1**. Patients with higher CRP

51
52
53 levels were more likely to have diabetes mellitus, a lower diastolic or mean BP, and a

54
55
56 higher heart rate than those with lower CRP levels. Patients with higher CRP levels had
57
58
59

1
2
3 lower levels of hemoglobin, sodium, and eGFR, but higher BNP levels than those with
4
5
6
7 lower CRP levels. Furthermore, we found that patients with higher CRP levels were less
8
9
10 likely to use beta blockers than those with lower CRP levels.
11
12
13
14
15
16

17 **Outcomes**

18
19
20
21 At a median follow-up of 2.0 years (interquartile range: 3.2 years), 142 patients had
22
23
24 died (27%) including 19 (16.7%) in Q1, 31 (21.1%) in Q2, 49 (36.6%) in Q3, and 43
25
26
27 (32.6%) in Q4. The cumulative survival curves significantly differed across CRP
28
29
30 quartiles (overall log-rank test, $p < 0.001$); the higher the CRP levels, the worse the
31
32
33 survival (log-rank trend test, $p < 0.001$) (**Figure 1**). Although patients in Q2 had a
34
35
36 1.4-times greater risk of mortality compared with those in Q1, the univariate analysis
37
38
39 did not reach statistical significance (HR: 1.40, 95% CI: 0.79–2.47, $p = 0.251$). On the
40
41
42 other hand, patients in Q3 and Q4 were at a significantly increased risk of mortality
43
44
45 compared to those in Q1 (HR: 2.69, 95% CI: 1.59–4.58, $p < 0.001$, and HR: 2.62, 95%
46
47
48 CI: 1.53–4.50, $p < 0.001$, respectively). Among each serum CRP quartile, the HR for
49
50
51 mortality significantly increased as the CRP level increased (p -value for HR trend; $<$
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 0.001). In addition, the log-transformed CRP level was associated with an increased risk
4
5
6
7 of mortality (HR: 1.23, 95% CI: 1.12–1.36, $p < 0.001$) suggesting that there is a
8
9
10 dose-dependent relationship between CRP levels and long-term mortality. Other
11
12
13 variables with p values < 0.1 in the univariate analyses were age, sex, BMI, history of
14
15
16
17 ADHF, ischemic heart disease, AF, diabetes mellitus, NYHA functional class, mean BP,
18
19
20
21 hemoglobin, eGFR, serum sodium and potassium, and the use of diuretics.
22
23

24 **Figure 2** shows the results of multivariable regression analyses. In terms of
25
26
27 long-term mortality, even in the multivariable analysis, patients in Q4 were at an
28
29
30 increased risk compared to those in Q1 (HR: 2.20, 95% CI: 1.10–4.38, $p = 0.026$),
31
32
33
34
35 whereas the HRs of those in Q2 and Q3 were attenuated and either became, or remained,
36
37
38 insignificant. The other variables in this multivariate analysis are summarized in **Table**
39
40
41
42 **2**. In multivariable analysis, the HR of each CRP quartile increased significantly as the
43
44
45 CRP quartiles increased (p -value for HR trend: 0.034, **Figure 2**). Similarly, the results
46
47
48 of multivariable analysis in which the CRP level was treated as a continuous variable
49
50
51 indicated that the greater the CRP level, the greater the risk of all-cause mortality (HR:
52
53
54
55
56 1.16, 95% CI: 1.01–1.32, $p = 0.030$, **Figure 2**).
57
58
59

1
2
3 **DISCUSSION**
4
5
6

7 The results of the present study provide several important insights into the association
8
9
10 between CRP levels and clinical outcomes in patients with ADHF. First, ADHF patients
11
12
13 in the highest admission CRP quartile (i.e., Q4: CRP \geq 3.9 mg/dL) had a significantly
14
15
16 greater risk of long-term mortality compared with those in the lowest CRP quartile (i.e.,
17
18
19 Q1: $<$ 0.3 mg/dL), even after the adjustment of confounding factors. Secondly, in the
20
21
22 multivariable analysis, the HR for mortality increased significantly as the admission
23
24
25 CRP level increased (p-value for HR trend: $<$ 0.001). Thirdly, there was a significant
26
27
28 dose-dependent relationship between the admission CRP level as a continuous variable
29
30
31 and the risk of long-term mortality. These findings suggest that CRP levels on
32
33
34 admission for ADHF can be a predictor of long-term mortality, and therefore, increased
35
36
37 levels of admission CRP have prognostic value for long-term outcomes in patients with
38
39
40
41
42
43
44
45
46 ADHF.
47
48

49 In patients with ADHF, hemodynamic changes trigger neurohormonal
50
51
52 activation, which has been considered a major cause of cardiac remodeling,
53
54
55
56 consequently leading to the progression of HF [16]. Inflammation is thought to be an
57
58
59

1
2
3 important contributor to the pathogenesis of ADHF and/or the progression of HF itself
4
5
6
7 [17, 18, 19, 20, 21, 22]. [17-22] There are obvious associations between inflammatory
8
9
10 mediators and various cardiovascular conditions such as coronary artery disease [23, 24,
11
12
13 25],[23-25] AF [26], and valvular heart disease [27], which can play important roles in
14
15
16 the onset of ADHF or the progression of HF. In these contexts, inflammation may
17
18
19
20
21 simply be an indicator of alterations in the underlying cardiovascular condition in
22
23
24 ADHF patients. However, several studies have shown that inflammatory cytokines,
25
26
27 including tumor necrotic factor (TNF)- α and interleukin (IL)-1 β , have direct negative
28
29
30 effects on cardiomyocytes by causing a Ca²⁺ imbalance following the suppression of
31
32
33 Ca²⁺-regulating gene expression in the sarcoplasmic reticulum. This ultimately leads to
34
35
36 cardiac dysfunction and the development of ADHF and/or the progression of HF [28, 29,
37
38
39 30]. [28-30] Furthermore, these cytokines are known to increase angiotensin II type 1
40
41
42 receptors, tumor growth factor (TGF)- β , and lysyl oxidase, all of which stimulate
43
44
45
46 cardiac fibroblasts leading to cardiac dysfunction and subsequent development of
47
48
49 ADHF and/or the progression of HF [31, 32, 33]. [31-33] Conversely, ADHF episodes
50
51
52
53 may induce inflammation; indeed, TNF- α , IL-6, and IL-18 are secreted from the
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 myocardium in response to mechanical stretch following hemodynamic overload [34].
4
5

6
7 In addition, increased monocyte differentiation is observed in the bone marrow of
8
9
10 patients with HF [35]. Mesenteric congestion causes bacterial translocation, and as a
11
12
13 result, the serum endotoxin levels increase and activate the immune system [36].
14
15
16

17 In patients with ADHF, elevated admission CRP levels can be associated with
18
19
20 concomitant infections. In terms of such concomitant infections, procalcitonin (PCT), a
21
22
23 precursor peptide of calcitonin and a specific marker of bacterial infection, has become
24
25
26 a recent focus in patients with HF. The response of PCT is both faster and greater than
27
28
29 CRP [37], and PCT has a pivotal role in decision making for the prescription of
30
31
32 antibiotics for patients with ADHF [38]. Furthermore, Meisel et al. [39] reported that
33
34
35 patients with ADHF and high PCT levels had worse outcomes unless they received
36
37
38 antibiotics [39], and the use of PCT in ADHF is recommended in the latest European
39
40
41 Society of Cardiology (ESC) guidelines [40]. However, it is not conclusive whether
42
43
44 PCT is a prognostic marker of ADHF patients without concomitant bacterial infections
45
46
47 [38]. These results may imply that PCT is sensitive to bacterial infections, but not
48
49
50 reflective of non-bacterial inflammation in patients with HF. Unlike PCT, CRP is a
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 comprehensive downstream marker which represents systemic or cardiac (i.e., local)
4
5
6
7 inflammation of a bacterial or non-bacterial nature which can be associated with the
8
9
10 development or progression of HF in ADHF patients.
11

12
13
14 Alonso-Martinez and colleagues [41] reported that elevated CRP levels on
15
16
17 admission (> 0.9 mg/dL) in ADHF patients was a risk factor for re-admission within 18
18
19
20 months [41]. Furthermore, Siirila-Waris and colleagues [42] reported that higher CRP
21
22
23 levels (>1.0 mg/dL) on admission were significantly associated with 12-month all-cause
24
25
26 mortality following ADHF regardless of a diagnosis of concomitant infection [42].
27
28

29
30
31 Minami and colleagues [43] clearly showed that markedly elevated CRP levels on
32
33
34 admission for ADHF (> 11.8 mg/dL) were associated with all-cause mortality; however,
35
36
37 in long-term follow-ups (> 120 days), the association between markedly elevated
38
39
40 admission CRP levels and mortality was prominent in non-cardiac causes [43]. On the
41
42
43 other hand, modestly elevated CRP levels on admission (2.9–11.8 mg/dL) were not
44
45
46 associated with mortality within a 120-day follow-up period [43]. However, modestly
47
48
49 elevated CRP levels on admission were associated with mortality in long-term
50
51
52
53 follow-up (> 120 days). Taken together, modestly elevated admission CRP levels in
54
55
56
57
58
59

1
2
3 ADHF patients may be a predictor for long-term mortality in association with chronic
4
5
6
7 localized cardiac inflammation, compared with markedly elevated CRP levels which are
8
9
10 reflective of systemic inflammation. Although admission CRP levels can indicate
11
12
13 different etiologies for the elevation of CRP levels, it is clear that elevated CRP levels
14
15
16
17 on admission for ADHF, even modest ones, can be a predictor of increased all-cause
18
19
20
21 mortality. Thus, the results of the present study are in line with this context.
22
23

24 Whether elevated admission CRP levels in patients with ADHF are causes or
25
26
27 consequences of HF remains unclear. In line with this, clinical studies to determine
28
29
30 whether increased CRP levels are a promising therapeutic target in patients with ADHF
31
32
33
34 are required. Aspirin and statin have anti-inflammatory effects [44, 45] and β -blockers,
35
36
37
38 angiotensin converting enzyme inhibitors (ACE-Is), and angiotensin II receptor
39
40
41
42 blockers (ARBs) also modulate inflammation in patients with HF [9, 46, 47]. However,
43
44
45
46 in some patients, inflammation is not sufficiently suppressed even with optimized
47
48
49
50 medical therapy; possibly due to the multifactorial role of inflammation in ADHF as
51
52
53 mentioned previously and might explain why anti-inflammatory strategies for HF have
54
55
56
57 not yet achieved satisfactory results [48, 49]. On the other hand, canakinumab, a
58
59
60
61
62
63
64
65

1
2
3 monoclonal antibody targeting IL-1 β , has been shown to drastically reduce recurrent
4
5
6
7 cardiovascular events in a pathway independent from lipid metabolism: Canakinumab
8
9
10 Anti-inflammatory Thrombosis Outcomes Study (CANTOS) [50]. This sub-study
11
12
13 revealed that canakinumab significantly improved the exercise capacity and LVEF in 30
14
15
16 patients with systolic HF (LVEF < 50%) and elevated CRP levels (> 2 mg/dL) [51]. In
17
18
19 patients with increased CRP levels and ADHF, there are small randomized double-blind
20
21
22
23 placebo controlled trials using anakinra, a recombinant IL-1 receptor antagonist. Van
24
25
26
27 Tassel and colleagues [52] showed that anakinra reduced CRP by approximately 60% vs.
28
29
30 baseline at 72 hours, compared with a 6% reduction among patients who received a
31
32
33 placebo. This was accompanied by a significant improvement in LVEF (+10% from
34
35
36 baseline) by anakinra compared with a placebo (0%) at 2 weeks [52]. In the Recently
37
38
39 Decompensated Heart Failure Anakinra Response Trial (REDHART), ADHF patients
40
41
42
43 with increased CRP levels were randomly assigned to daily administration of anakinra
44
45
46
47 for 2 weeks, 12 weeks, or a placebo in order to investigate whether anakinra could
48
49
50
51 improve exercise capacity through the inhibition of inflammatory response. Although no
52
53
54
55
56 change in exercise capacity occurred at 2 weeks in patients taking anakinra, an
57
58
59
60
61
62
63
64
65

1
2
3 improvement was observed in patients when anakinra was continued for 12 weeks [53].
4
5

6
7 These findings at least partially suggested that increased CRP levels might be a
8
9

10
11 promising therapeutic target in patients with ADHF.
12

13
14 Our study is subject to some limitations. First, it was limited to a single
15
16
17 academic center and included only a Japanese patient population. Secondly, since the
18
19
20 present study was observational in nature, even after the adjusted analysis, other
21
22
23 confounders which might have affected the results cannot be ruled out. Despite these
24
25
26 limitations, our study highlights that in ADHF patients, the greater the CRP level at
27
28
29 admission, the poorer the long-term outcome.
30
31
32
33
34
35
36
37

38 39 **CONCLUSION**

40
41
42 The admission CRP level was associated with an increased risk of long-term mortality
43
44
45 in patients with ADHF. CRP was an independent prognostic factor, even following
46
47
48 hospital discharge in patients with ADHF. Although a close association between
49
50
51 inflammation and ADHF has been indicated for years, clinical evidence remains limited.
52
53
54
55
56 Further investigations with a larger sample size are required to determine novel
57
58
59
60
61
62
63
64
65

1
2
3 treatments which can modify CRP levels in patients with ADHF.
4
5
6
7
8
9

10 **FUNDING**

11
12 A grant was awarded to The Intractable Respiratory Diseases and Pulmonary
13
14
15

16
17 Hypertension Research Group, from the Ministry of Health, Labor and Welfare,
18
19

20
21 Grant/Award Number: H29-027; Health, Labour and Welfare Sciences Research Grants,
22
23

24
25 Research on Region Medical, Grant/Award Number: H30-iryuu-ippan-009;
26
27

28
29 MEXT-Supported Program for the Strategic Research Foundation at Private
30
31

32
33 Universities, 2014-2018 (Ministry of Education, Culture, Sports, Science and
34
35

36
37 Technology); JSPS KAKENHI, Grant/Award Number: JP17K09527.
38
39
40
41

42 **CONFLICT OF INTEREST**

43
44
45 Drs. Hiroki Matsumoto, Takatoshi Kasai, Akihiro Sato, Sayaki Ishiwata, and Yuya
46
47

48
49 Matsue are affiliated with a department endowed by Philips Respironics, ResMed, and
50
51

52
53 Fukuda Denshi. Dr. Hiroyuki Daida received research grants from various
54
55

56
57 pharmaceutical companies and payment for lectures, including service in speakers'
58
59

1
2
3 bureaus from Medtronic Japan, AstraZeneca K.K., MSD K.K., Ono Pharmaceutical Co.
4
5
6
7 Ltd, GlaxoSmithKline K.K., Shionogi & Co. Ltd, Daiichi Sankyo Company, Takeda
8
9
10 Pharmaceutical Co. Ltd, Nippon Boehringer Ingelheim Co. Ltd, Bayer Yakuhin, Ltd,
11
12
13 Terumo Corporation, and Astellas Pharma Inc. The other authors report no conflicts of
14
15
16
17 interest.
18
19
20
21
22
23

24 **REFERENCES**

- 25
26
27
28 1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats
29
30 TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver
31
32 MA, Stevenson LW, Yancy CW, American College of Cardiology F and American
33
34
35 Heart A (2009) Focused update incorporated into the ACC/AHA 2005
36
37
38 guidelines for the diagnosis and management of heart failure in adults: a report
39
40
41
42 of the American College of Cardiology Foundation/American Heart Association
43
44
45
46 Task Force on practice guidelines developed in collaboration with the
47
48
49
50
51
52
53 International Society for Heart and Lung Transplantation. J Am Coll Cardiol
54
55
56 53:e1–e90
57
58
59
60
61
62
63
64
65

- 1
2
3 2. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013)
4
5
6
7 Rehospitalization for heart failure: problems and perspectives. *J Am Coll Cardiol*
8
9
10 61:391–403
11
- 12
13 3. Januzzi JL Jr., Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones
14
15
16
17 DM (2010) Importance of biomarkers for long-term mortality prediction in
18
19
20
21 acutely dyspneic patients. *Clin Chem* 56:1814–1821
22
- 23
24 4. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR,
25
26
27
28 Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B,
29
30
31
32 O'Connor CM (2014) Noncardiac comorbidities in heart failure with reduced
33
34
35 versus preserved ejection fraction. *J Am Coll Cardiol* 64:2281–2293
36
- 37
38 5. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S,
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
2. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J
(2003) Invasive assessment of bacterial endotoxin and inflammatory cytokines in

1
2
3 patients with acute heart failure. *Eur J Heart Fail* 5:609–614
4
5

6
7 7. Milo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, Vered Z,
8
9
10 Hershkoviz R (2003) Comparison of inflammatory and neurohormonal
11
12
13 activation in cardiogenic pulmonary edema secondary to ischemic versus
14
15
16
17 nonischemic causes. *Am J Cardiol* 92:222–226
18
19

20
21 8. Tillett WS, Francis T (1930) Serological reactions in pneumonia with a
22
23
24 non-protein somatic fraction of pneumococcus. *J Exp Med* 52:561–571
25
26

27
28 9. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S,
29
30
31 Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-He FTI (2005)
32
33
34
35 C-reactive protein in heart failure: prognostic value and the effect of valsartan.
36
37
38
39 *Circulation* 112:1428–434
40

41
42 10. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG
43
44
45 (2007) Relationship of high-sensitivity C-reactive protein to prognosis and other
46
47
48
49 prognostic markers in outpatients with heart failure. *Am Heart J* 153:1048–1055
50
51

52
53 11. Tanner H, Mohacsi P, Fuller-Bicer GA, Rieben R, Meier B, Hess O,
54
55
56
57 Hullin R (2007) Cytokine activation and disease progression in patients with
58
59

1
2
3 stable moderate chronic heart failure. *J Heart Lung Transplant* 26:622–629
4
5

6
7 12. Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Allen Maycock CA,
8
9
10 Bair TL, Carlquist JF, Kfoury AG, Anderson JL, Renlund DG, International
11
12
13 Heart Collaborative Study G (2005) C-reactive protein predicts death in patients
14
15
16
17 with non-ischemic cardiomyopathy. *Cardiology* 104:196–201
18
19
20

21 13. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M (2006)
22
23
24 Prediction of mortality by high-sensitivity C-reactive protein and brain
25
26
27
28 natriuretic peptide in patients with dilated cardiomyopathy. *Circ J* 70:857–863
29
30

31 14. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The
32
33
34
35 natural history of congestive heart failure: The Framingham Study. *N Engl J Med*
36
37
38
39 285:1441–1446
40
41

42 15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K,
43
44
45 Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese
46
47
48
49 equation for estimated GFR (2009) Revised equations for estimated GFR from
50
51
52
53 serum creatinine in Japan. *Am J Kidney Dis* 53:982–992
54
55

56 16. Packer M (1992) The neurohormonal hypothesis: a theory to explain
57
58
59

1
2
3 the mechanism of disease progression in heart failure. *J Am Coll Cardiol* 20:248–

4
5
6
7 254

8
9
10 17. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated

11
12
13 circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl*

14
15
16
17 *J Med* 323:236–241

18
19
20 18. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A,

21
22
23
24 Cassani G, Visioli O (1995) Tumor necrosis factor soluble receptors in patients

25
26
27 with various degrees of congestive heart failure. *Circulation* 92:1479–1486

28
29
30 19. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal

31
32
33
34 C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD (2000) Plasma cytokine

35
36
37 parameters and mortality in patients with chronic heart failure. *Circulation*

38
39
40
41
42 102:3060–3067

43
44
45 20. Miettinen KH, Lassus J, Harjola VP, Siirila-Waris K, Melin J,

46
47
48
49 Punnonen KR, Nieminen MS, Laakso M, Peuhkurinen KJ (2008) Prognostic role

50
51
52 of pro- and anti-inflammatory cytokines and their polymorphisms in acute

53
54
55
56 decompensated heart failure. *Eur J Heart Fail* 10:396–403

- 1
2
3 21. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T,
4
5
6 Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB, Framingham
7
8
9 Heart S (2003) Inflammatory markers and risk of heart failure in elderly subjects
10
11
12 without prior myocardial infarction: the Framingham Heart Study. *Circulation*
13
14
15
16
17 107:1486–1491
18
19
20
21 22. Van Linthout S, Tschope C (2017) Inflammation - cause or
22
23
24 consequence of heart failure or both? *Curr Heart Fail Rep* 14:251–265
25
26
27
28 23. Tian M, Yuan YC, Li JY, Gionfriddo MR, Huang RC (2015) Tumor
29
30
31 necrosis factor-alpha and its role as a mediator in myocardial infarction: a brief
32
33
34 review. *Chronic Dis Transl Med* 1:18–26
35
36
37
38 24. Gabriel AS, Martinsson A, Wretling B, Ahnve S (2004) IL-6 levels in
39
40
41 acute and post myocardial infarction: their relation to CRP levels, infarction size,
42
43
44 left ventricular systolic function, and heart failure. *Eur J Intern Med* 15:523–528
45
46
47
48
49 25. Toldo S, Van Tassell BW, Abbate A (2017) Interleukin-1 blockade in
50
51
52 acute myocardial infarction and heart failure: getting closer and closer. *JACC*
53
54
55
56 Basic Transl Sci 2:431–433
57
58
59

- 1
2
3 26. Hu YF, Chen YJ, Lin YJ, Chen SA (2015) Inflammation and the
4
5
6
7 pathogenesis of atrial fibrillation. *Nat Rev Cardiol* 12:230–243
8
9
10
11 27. Cote N, Mahmut A, Bosse Y, Couture C, Page S, Trahan S, Boulanger
12
13 MC, Fournier D, Pibarot P, Mathieu P (2013) Inflammation is associated with
14
15 the remodeling of calcific aortic valve disease. *Inflammation* 36:573–581
16
17
18
19
20
21 28. Wu CK, Lee JK, Chiang FT, Yang CH, Huang SW, Hwang JJ, Lin JL,
22
23
24 Tseng CD, Chen JJ, Tsai CT (2011) Plasma levels of tumor necrosis factor-alpha
25
26 and interleukin-6 are associated with diastolic heart failure through
27
28
29
30
31 downregulation of sarcoplasmic reticulum Ca²⁺ ATPase. *Crit Care Med* 39:984–
32
33
34
35 992
36
37
38
39 29. Thaik CM, Calderone A, Takahashi N, Colucci WS (1995)
40
41
42 Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac
43
44
45 myocytes. *J Clin Invest* 96:1093–1099
46
47
48
49 30. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL
50
51
52 (1993) Cellular basis for the negative inotropic effects of tumor necrosis
53
54
55
56 factor-alpha in the adult mammalian heart. *J Clin Invest* 92:2303–2312
57
58
59

- 1
2
3 31. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg
4
5
6
7 BH (2005) IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1)
8
9
10 receptors on cardiac fibroblasts and are associated with increased AT1 density in
11
12
13 the post-MI heart. *J Mol Cell Cardiol* 38:505–515
14
15
16
17 32. Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR (2009)
18
19
20
21 TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the
22
23
24 transcriptional level via AP-1 activation. *J Cell Mol Med* 13:1866–1876
25
26
27
28 33. Voloshenyuk TG, Hart AD, Khoutorova E, Gardner JD (2011)
29
30
31
32 TNF-alpha increases cardiac fibroblast lysyl oxidase expression through
33
34
35 TGF-beta and PI3Kinase signaling pathways. *Biochem Biophys Res Commun*
36
37
38 413:370–375
39
40
41
42 34. Yoshida T, Friehs I, Mummidi S, del Nido PJ, Addulnour-Nakhoul S,
43
44
45
46 Delafontaine P, Valente AJ, Chandrasekar B (2014) Pressure overload induces
47
48
49 IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a
50
51
52
53 rabbit model. IL-18 potentiates TNF-alpha-induced cardiomyocyte death. *J Mol*
54
55
56
57 *Cell Cardiol* 75:141–151
58
59
60
61
62
63
64
65

- 1
2
3 35. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M,
4
5
6
7 Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y, Weissleder R, Libby P, Swirski FK,
8
9
10 Nahrendorf M (2015) Targeting Interleukin-1beta Reduces Leukocyte
11
12
13
14 Production After Acute Myocardial Infarction. *Circulation* 132:1880–1890
15
16
17 36. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR,
18
19
20
21 Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD (1999) Endotoxin and
22
23
24 immune activation in chronic heart failure: a prospective cohort study. *Lancet*
25
26
27
28 353:1838–1842
29
30
31 37. Wang W, Zhang X, Ge N, Liu J, Yuan H, Zhang P, Liu W, Wen D
32
33
34
35 (2014) Procalcitonin testing for diagnosis and short-term prognosis in bacterial
36
37
38 infection complicated by congestive heart failure: a multicenter analysis of 4,698
39
40
41
42 cases. *Crit Care* 18:R4
43
44
45 38. Mockel M, Searle J, Maisel A (2017) The role of procalcitonin in acute
46
47
48
49 heart failure patients. *ESC Heart Fail* 4:203–208
50
51
52 39. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF,
53
54
55
56 Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos
57
58
59

1
2
3 GS, Di Somma S, Anand I, Ng LL, Daniels LB, Christenson RH, Potocki M,
4
5
6
7 McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenthaler NG, Anker
8
9
10 SD (2012) Use of procalcitonin for the diagnosis of pneumonia in patients
11
12
13 presenting with a chief complaint of dyspnoea: results from the BACH
14
15
16
17 (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 14:278–286
18
19

20
21 40. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS,
22
23
24 Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
25
26
27 Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
28
29
30
31 Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD (2016) 2016 ESC
32
33
34 guidelines for the diagnosis and treatment of acute and chronic heart failure: the
35
36
37 task force for the diagnosis and treatment of acute and chronic heart failure of
38
39
40
41 the European Society of Cardiology (ESC) developed with the special
42
43
44 contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
45
46
47
48
49 37:2129–2200
50

51
52
53 41. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M,
54
55
56 Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C (2002)
57
58
59

1
2
3 C-reactive protein as a predictor of improvement and readmission in heart
4
5
6
7 failure. *Eur J Heart Fail* 4:331–336
8
9

10 42. Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS,
11
12 Harjola VP, Group F-AS (2006) Characteristics, outcomes, and predictors of
13
14 1-year mortality in patients hospitalized for acute heart failure. *Eur Heart J*
15
16
17
18
19
20
21 27:3011–3017
22
23

24 43. Minami Y, Kajimoto K, Sato N, Hagiwara N, Takano T, Investigators
25
26 AS (2017) C-reactive protein level on admission and time to and cause of death
27
28 in patients hospitalized for acute heart failure. *Eur Heart J Qual Care Clin*
29
30
31
32
33
34
35 Outcomes 3:148–156
36
37

38 44. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH
39
40
41
42 (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently
43
44
45
46 healthy men. *N Engl J Med* 336:973–979
47
48

49 45. Vogiatzi G, Oikonomou E, Siasos G, Tsalamandris S, Briasoulis A,
50
51
52 Androulakis E, Latsios G, Papaioannou S, Tsioufis K, Tousoulis D (2017)
53
54
55
56 Statins and inflammation in cardiovascular disease. *Curr Pharm Des* doi:
57
58
59

1
2
3 10.2174/1381612823666171009141201
4
5

6
7 46. Calo LA, Semplicini A, Davis PA (2005) Antioxidant and
8
9 antiinflammatory effect of carvedilol in mononuclear cells of hypertensive
10
11 patients. *Am J Med* 118:201–202
12
13

14
15
16
17 47. Kurum T, Tatli E, Yuksel M (2007) Effects of carvedilol on plasma
18
19 levels of pro-inflammatory cytokines in patients with ischemic and nonischemic
20
21 dilated cardiomyopathy. *Tex Heart Inst J* 34:52–59
22
23
24

25
26
27
28 48. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ,
29
30 Feldman AM, Mann DL (2001) Results of targeted anti-tumor necrosis factor
31
32 therapy with etanercept (ENBREL) in patients with advanced heart failure.
33
34
35
36
37
38
39 *Circulation* 103:1044–1047
40
41

42
43 49. Anker SD, Coats AJ (2002) How to recover from renaissance? The
44
45 significance of the results of recover, renaissance, renewal and attach. *Int J*
46
47
48
49
50
51
52 *Cardiol* 86:123–130

53
54 50. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH,
55
56
57
58
59
60
61
62
63
64
65 Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel

1
2
3 JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z,
4
5
6
7 Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF,
8
9
10 Troquay RPT, Libby P, Glynn RJ, Group CT (2017) Antiinflammatory therapy
11
12
13 with Canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131
14

15
16
17 51. Trankle CR, Canada JM, Cei L, Abouzaki N, Oddi-Erdle C, Kadariya D,
18
19
20 Christopher S, Viscusi M, Del Buono M, Kontos MC, Arena R, Van Tassell B,
21
22
23
24 Abbate A (2018) Usefulness of Canakinumab to improve exercise capacity in
25
26
27 patients with long-term systolic heart failure and elevated C-reactive protein. Am
28
29
30
31 J Cardiol 122:1366–1370
32

33
34
35 52. Van Tassell BW, [Abouzaki NA](#), [Oddi Erdle C](#), [Carbone S](#), [Trankle](#)
36
37
38 [CR](#), [Melchior RD](#), [Turlington JS](#), [Thurber CJ](#), [Christopher S](#), [Dixon DL](#), [Fronk](#)
39
40
41 [DT](#), [Thomas CS](#), [Rose SW](#), [Buckley LF](#), [Dinarello CA](#), [Biondi-Zoccai G](#), [Abbate](#)
42
43
44 [A](#) (2016) Interleukin-1 Blockade in Acute Decompensated Heart Failure: A
45
46
47
48
49 Randomized, Double-Blinded, Placebo-Controlled Pilot Study. J Cardiovasc
50
51
52
53 Pharmacol 67:544–551
54

55
56 53. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Erdle C, Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J,
Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R,
Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A (2017) Interleukin-1 Blockade
in Recently Decompensated Systolic Heart Failure: Results From REDHART
(Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart
Fail 10:e004373

1
2
3 **Figure legends**
4
5

6 **Figure 1: Cumulative survival according to CRP quartiles.**

7
8 P values for overall log-rank tests indicate whether there is a difference in the four
9 different survival curves ($p < 0.001$). P values for the log-rank trend test indicate
10 whether increased levels of CRP are associated with increased cumulative mortality (p
11 < 0.001).
12
13

14 *Abbreviations:* CRP: C-reactive protein
15
16

17
18 **Figure 2: Forest plots of multivariable analyses**
19

20 In the multivariable analysis, patients in Q4 were at an increased risk for long-term
21 mortality compared to those in Q1, and the HR of each CRP quartile significantly
22 increased as the CRP quartiles increased. In multivariable analysis in which the CRP
23 level was treated as a continuous variable, the greater the CRP level, the greater the risk
24 of all-cause mortality.
25
26
27

28 *Abbreviations:* CRP: C-reactive protein, Ln-: logarithm-transformed, HR: Hazard ratio
29
30
31

32
33 **Table legends**

34 **Table 1: Baseline characteristics**

35
36 Data are expressed as mean \pm standard deviation or median (interquartile range) for
37 continuous variables, and numbers (%) for nominal variables.
38

39 *Abbreviations:* ADHF: acute decompensated heart failure, ACE-Is: angiotensin
40 converting enzyme inhibitors, ARBs: angiotensin II receptor blockers, BMI: body mass
41 index, BNP: B-type natriuretic peptide, BP: blood pressure, CRP: C-reactive protein,
42 eGFR: estimated glomerular filtration rate, LVEF: left ventricular ejection fraction,
43 NYHA: New York Heart Association.
44
45
46
47
48

49
50 **Table 2:**

51 *Abbreviations:* ADHF: acute decompensated heart failure, BMI: body mass index, BP:
52 blood pressure, CI: confidence interval, CRP: C-reactive protein, eGFR, estimated
53 glomerular filtration rate, HR: hazard ratio
54
55
56
57
58
59


Table 1


	CRP levels per quartile				P
	Q1 [< 0.3 mg/dl] (N = 114)	Q2 [0.3–1.0 mg/dl] (N = 147)	Q3 [1.0–3.9 mg/dl] (N = 134)	Q4 [≥ 3.9 mg/dl] (N = 132)	
Age, years	69.7 ± 12.3	70.5 ± 13.6	71.0 ± 14.7	71.0 ± 14.2	0.877
Men, n (%)	69 (61)	100 (68)	81 (60)	87 (66)	0.462
BMI, kg/m ²	22.6 ± 4.1	23.4 ± 4.9	23.1 ± 5.9	22.3 ± 4.7	0.307
Current smokers, n (%)	53 (46)	67 (46)	61 (46)	55 (42)	0.869
History of ADHF, n (%)	59 (52)	68 (46)	74 (55)	72 (55)	0.418
NYHA class	3 (1)	3 (1)	4 (1)	4 (1)	0.002
Ischemic heart disease, n (%)	44 (39)	50 (34)	60 (45)	58 (44)	0.222
Atrial fibrillation, n (%)	47 (41)	57 (39)	46 (34)	46 (35)	0.630
Diabetes mellitus, n (%)	38 (33)	48 (33)	47 (35)	64 (48)	0.024
Chronic pulmonary disease, n (%)	6 (5)	5 (3)	10 (7)	8 (6)	0.507
Systolic BP, mmHg	142.1 ± 31.0	139.8 ± 37.5	134.1 ± 32.5	131.4 ± 28.5	0.056
Diastolic BP, mmHg	79.0 ± 20.5	78.2 ± 22.2	73.6 ± 19.5	72.6 ± 16.9	0.035
Mean BP, mmHg	99.8 ± 21.4	98.6 ± 25.3	93.9 ± 22.2	92.2 ± 18.4	0.028

Heart rate, <i>/min</i>	89.4 ± 28.1	89.6 ± 30.0	94.5 ± 29.9	98.7 ± 27.1	0.042
LVEF, %	44.7 ± 18.0	42.3 ± 17.2	43.9 ± 18.8	41.6 ± 16.5	0.484
Hemoglobin, <i>g/dl</i>	12.7 ± 2.9	12.6 ± 2.6	11.7 ± 2.5	11.5 ± 2.5	< 0.001
eGFR, <i>ml/min/1.73</i> <i>m²</i>	62.1 ± 32.0	48.3 ± 22.1	47.8 ± 25.9	48.0 ± 30.0	< 0.001
Sodium, <i>mmol/l</i>	140.0 ± 3.6	139.4 ± 3.5	137.5 ± 4.7	136.4 ± 5.4	< 0.001
Potassium, <i>mmol/l</i>	4.2 ± 0.5	4.3 ± 0.7	4.3 ± 0.8	4.3 ± 0.8	0.448
CRP, <i>mg/dl</i>	0.1 (0.1)	0.5 (0.3)	1.9 (1.3)	9.1 (8.5)	< 0.001
BNP, <i>pg/ml</i>	480.5 (597.5)	613.4 (962.4)	864.3 (1205.3)	689.7 (998.9)	0.003
<u>Medication</u> <u>before</u> <u>admission</u>					
Beta blockers, <i>n</i> (%)	46 (40.4)	44 (29.9)	49 (36.6)	31 (23.5)	0.023
ACE-Is /ARBs, <i>n</i> (%)	47 (41.2)	28 (19.0)	59 (44.0)	41 (31.1)	0.159
Aldosterone blockers, <i>n</i> (%)	12 (10.5)	7 (10.4)	23 (17.2)	14 (10.6)	0.101
Diuretics, <i>n</i> (%)	42 (36.8)	67 (45.5)	65 (48.5)	46 (34.8)	0.068

Table2

	HR	95% CI		P
		Lower	Upper	
Age	1.026	1.003	1.049	0.024
Men	0.870	0.562	1.346	0.531
BMI	0.942	0.887	1.002	0.056
History of ADHF	1.529	0.972	2.405	0.066
NYHA class	0.979	0.726	1.321	0.892
Ischemic heart disease	1.022	0.638	1.639	0.927
Atrial fibrillation	1.552	0.958	2.513	0.074
Mean BP	0.992	0.981	1.003	0.157
Diabetes mellitus	1.404	0.881	2.238	0.154
Hemoglobin	0.846	0.763	0.938	0.002
Sodium	0.966	0.916	1.019	0.210
Potassium	1.097	0.833	1.446	0.510
eGFR	1.003	0.994	1.012	0.506
Diuretics	1.909	1.205	3.024	0.006





Original Research Cover Letter

January 16, 2019

Nobuhisa Hagiwara
Editor-in-chief, Heart and Vessels
Tokyo, Japan

Sachiko Hayakawa
Publishing Editor, Heart and Vessels
101-0065 Nishi-Kanda 3-8-1
Tokyo, Japan

Dear Dr. Hagiwara and Dr. Hayakawa;

On behalf of all the authors, I would like to ask you to consider our manuscript entitled “Association between C-reactive protein level at hospital admission and long-term mortality in patients with acute decompensated heart failure” for publication in Heart and Vessels as an original research article.

We examined 527 consecutive patients with acute decompensated heart failure (ADHF) admitted to our institution from 2007 to 2011. Eligible patients were divided into four groups based on quartiles of the admission C-reactive protein (CRP) levels. There were 142 deaths (27%) during a median follow-up period of 2.0 years. In the multivariable analysis, the hazard ratio (HR) significantly increased with the admission CRP level in a dose-dependent manner for mortality (p for trend = 0.034). Multivariable analysis also showed a significant association between the admission CRP level, when treated as a natural logarithm-transformed continuous variable, and increased mortality (HR, 1.16, $p = 0.030$)

Although limited data are available regarding prognostic effect of the admission CRP level in patients with ADHF, we showed its association with long-term mortality and quantitative value. We feel that this study will be of special interest to the readers of Heart and Vessels.

This manuscript has not been published and is not under consideration for publication elsewhere. All the authors have read the manuscript and have approved this submission.

Sincerely,

Takatoshi Kasai, MD, PhD
Department of Cardiovascular Medicine, Juntendo University School of Medicine and Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital.
2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: kasai-t@mx6.nisiq.net
Phone: +81-3-3813-3111; Fax: +81-3-5689-0627